New Enterprise Associates 14, L.P.

Average Profitability
<0.0001%
Insider Buys Quantity
10
Insider Buys Sum
$124.03M
Insider Sells Quantity
4
Insider Sells Sum
$137.1M

Insider Activity of New Enterprise Associates 14, L.P.

The largest purchase of all time was on 2019-03-05 and amounted to 7500000 shares of Mersana Therapeutics, Inc. for $30M.

The largest sale of all time was on 2017-11-20 and amounted to 5641032 shares of Appian Corporation for $109.94M.

Biography of New Enterprise Associates 14, L.P.

No biography is available at this moment.

2020-03-06SaleChampions Oncology, Inc.
CSBR
10 percent owner
708,155
6.1742%
$6.99$4.95M+42.97%
2019-08-28SaleMersana Therapeutics, Inc.
MRSN
10 percent owner
2,422
0.006%
$2.91$7,048+203.64%
2019-03-05PurchaseMersana Therapeutics, Inc.
MRSN
10 percent owner
7.5M
23.242%
$4.00$30M-3.05%
2018-09-07PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
6M
0.9744%
$1.67$10M-57.66%
2018-03-27PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
12M
2.1988%
$1.92$23M-12.28%
2018-03-26PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
1.14M
0.2007%
$1.90$2.18M-14.01%
2018-03-23PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
588,180
0.1062%
$1.95$1.14M-12.52%
2018-03-22PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
1.74M
0.308%
$1.90$3.31M-12.12%
2018-03-21PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
209,688
0.0355%
$1.81$379,640-10.61%
2017-11-27SaleAppian Corporation
APPN
10 percent owner
1.14M
2.1156%
$19.49$22.2M+42.78%
2017-11-20SaleAppian Corporation
APPN
10 percent owner
5.64M
11.2735%
$19.49$109.94M+53.66%
2017-07-03PurchaseMersana Therapeutics, Inc.
MRSN
10 percent owner
2M
9.7597%
$15.00$30M+20.77%
2017-03-27PurchaseAdaptimmune Therapeutics plc
ADAP
10 percent owner
25.74M
5.5147%
$0.70$18.02M+55.36%
2015-10-06PurchaseSynlogic, Inc.
SYBX
10 percent owner
857,142
4.1031%
$7.00$6M-36.97%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.